Multimodal Discrimination of Alzheimer's Disease Based on Regional Cortical Atrophy and Hypometabolism.

ABSTRACT: Structural MR image (MRI) and 18F-Fluorodeoxyglucose-positron emission tomography (FDG-PET) have been widely employed in diagnosis of both Alzheimer's disease (AD) and mild cognitive impairment (MCI) pathology, which has led to the development of methods to distinguish AD and MCI from normal controls (NC). Synaptic dysfunction leads to a reduction in the rate of metabolism of glucose in the brain and is thought to represent AD progression. FDG-PET has the unique ability to estimate glucose metabolism, providing information on the distribution of hypometabolism. In addition, patients with AD exhibit significant neuronal loss in cerebral regions, and previous AD research has shown that structural MRI can be used to sensitively measure cortical atrophy. In this paper, we introduced a new meth

SUBMITTER: Yun HJ 

PROVIDER: S-EPMC4463854 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature